3p-C-NETA-TATE: a theranostic somatostatin analogue targeting neuroendocrine tumors

Stephen Ahenkorah, Erika Murce, Christopher Cawthorne, Yann Seimbille, Thomas Cardinaels, Christophe Deroose, Guy Bormans, Maarten Ooms, Frederik Cleeren

Research outputpeer-review

Abstract

Aim: Radiolabeled somatostatin analogues such as [68Ga]Ga-DOTATATE and [177Lu]Lu-DOTATATE have become important tools for diagnosis and treatment of patients with neuroendocrine tumors. [18F]AlF-NOTA-octreotide, a promising 18F-labeled somatostatin analogue and potential alternative for 68Ga-DOTA-peptides, is currently under clinical evaluation [1]. Ideally, the same precursor (combination of chelator-linker-vector) should be used for production of both diagnostic and therapeutic radioprobes to ensure very similar (e.g. Al18F/213Bi/177Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing for accurate personalised dosimetry estimation, and radionuclide therapy of NET patients. 3p-C-NETA is a versatile chelator that can be used for both diagnostic and therapeutic applications [2, 3]. We have recently reported promising results for [18F]AlF-3p-C-NETA-TATE [2] and here we present the first results of radiosynthesis and in vitro evaluation of [213Bi]Bi-3p-C-NETA-TATE and [177Lu]Lu-3p-C-NETA-TATE.
Original languageEnglish
Title of host publicationAbstracts from the 20th European symposium on radiopharmacy and radiopharmaceuticals
PublisherSpringer
Pages6-6
Number of pages1
Volume8
Edition1
DOIs
StatePublished - 15 Jun 2023
Event2022 - ERSS: 20th European symposium on radiopharmacy and radiopharmaceuticals - Verona
Duration: 24 Nov 202224 Nov 2022

Publication series

NameEJNMMI Radiopharmacy and Chemistry
PublisherSpringer
NumberSupplement 1
Volume8
ISSN (Electronic)2365-421X

Conference

Conference2022 - ERSS
Country/TerritoryItaly
CityVerona
Period2022-11-242022-11-24

Cite this